Front Aging Neurosci:Lipocalin-2 在卒中后抑郁模型中调节海马小胶质细胞的激活

2021-12-21 brainnew神内神外 网络

海马体参与学习、记忆、情绪等基本功能,海马的病理改变是各种神经疾病的基础,特别是抑郁症、痴呆症和癫痫



卒中后抑郁症(PSD)是卒中后遗症之一,严重影响卒中幸存者的生活质量,并与高死亡率相关。其病理可能是多因素的,涉及中风和抑郁症的发病机制的组合,目前研究尚未阐明其发病机制,严重影响对PSD的预防和治疗。抑郁症被描述为一种与小胶质细胞相关的疾病,除了细胞过度活化和细胞数量增加外,在一些抑郁症患者中还观察到小胶质细胞数量减少和衰老,而小胶质细胞激活与PSD密切相关。

Lipocalin-2 (LCN2) 是高度异质性的分泌蛋白 lipocalin 家族的成员,与细胞分化、细胞凋亡和细胞摄取铁的调节有关。LCN2由受伤的神经元释放,激活小胶质细胞和星形胶质细胞,使其具有潜在的促进恢复表型。小胶质细胞激活在PSD中起重要作用,而LCN2与小胶质细胞激活密切相关;但LCN2在PSD小胶质细胞激活中的确切作用和机制仍不清楚。来自浙江大学第一附属医院的研究团队旨在确定LCN2如何调节PSD中的小胶质细胞活化,为PSD的发病机制提供新的思路。

1、卒中后抑郁组1-3周LCN2浓度持续升高

与假手术(PS)组相比,PSD组血清LCN2浓度在术后1、2、3周显著升高。PSD组血清LCN2浓度在术后第2周较术后1周显着降低,在第3周升高(图1 A)。与生理盐水(Sham)组和PS组相比,PSD组LCN2的相对mRNA表达量显着增加(图1B)。PSD组中,LCN2 mRNA 左脑半球的相对表达量较右脑半球显著降低,右侧脑半球海马区LCN2 mRNA较左侧脑显着增加(图 1C);PS组不同脑区LCN2 mRNA相对表达量无显着差异(图1D)。
与中风后抑郁大鼠的其他区域相比,海马区域的 Iba1 蛋白水平增加。
图1 三组血清 LCN2 水平

2、中风后抑郁大鼠海马区Iba1、P38 MAPK蛋白水平和 PP 38/P38 比值增加

图2显示PSD组海马区Iba1、P38 MAPK和PP 38 MAPK相对蛋白水平,PSD组较sham组和PS组而言上述蛋白表达明显升高。与PS组相比,PSD组Iba1相对蛋白水平、P38 MAPK蛋白水平和pP38/P38MAPK比值均显着升高(图2)。
图2
(A)三组Iba1、P38 MAPK 和 PP38 MAPK 的印迹。(B) Iba1 的相对蛋白质水平(C) P38 MAPK 的相对蛋白质水平 (D) PP38/P38 MAPK比值

3、Lipocalin-2 刺激后小胶质细胞的变化

1 μg/ml LCN2处理24 h后,LCN2-MG组上清液中NO浓度较Con-MG组上清液显着升高(图3A)。LCN2-MG组明显长于 Con-MG组(图 3B),并且比 Con-MG组迁移的更多(图 3C)。LCN2-MG吞噬微球数量明显高于Con-MG组(图3D)。图3E、F显示 LCN2 增强了初级小胶质细胞的吞噬能力。最后,Lipocalin-2 处理的小胶质细胞中 Iba1、P38 MAPK 和 PP38 MAPK 蛋白水平增加。

图3 Lipocalin-2 刺激后小胶质细胞的变化

综上,作者研究发现LCN2可能通过P38/ MAPK 通路调节海马小胶质细胞的激活。

 

海马体参与学习、记忆、情绪等基本功能,海马的病理改变是各种神经疾病的基础,特别是抑郁症、痴呆症和癫痫。因此,研究海马小胶质细胞活化对于阐明PSD的机制具有重要意义。在之前的研究中,作者分析了PSD大鼠海马区、左右半脑小胶质细胞激活标志物的表达情况,发现海马比其他大脑区域有更多的小胶质细胞激活, PSD组大鼠海马区的小胶质细胞激活标志物 Iba1 的蛋白质水平显著增加。这表明海马的小胶质细胞在 PSD 中被激活,因此重点研究海马体。

 

在LCN2刺激后,初级小胶质细胞表现出明显的改变:小胶质细胞释放的NO量、小胶质细胞的长度、海马小胶质细胞的吞噬能力和迁移能力均显着增加。由于 P38 MAPK 和 LCN2 与小胶质细胞激活的密切关系,作者推测 LCN2可能通过P38/ MAPK 诱导小胶质细胞激活。因此,作者评估了 LCN2 刺激后海马小胶质细胞中 P38 MAPK 蛋白水平的变化,发现P38 MAPK 的相对蛋白水平显着增加。此外,PP38 MAPK蛋白水平也表现出同样显着的增加。P38 MAPK 和 PP38 MAPK 蛋白水平在PSD大鼠的海马中显示出与在培养的原代小胶质细胞中相同的变化。体外和体内结果均表明,LCN2通过在P38 MAPK途径调节海马小胶质细胞活化。

 

但是作者的研究存在局限性,作者研究的是整个海马区域,并没有区分不同的功能区域,所以需要进一步分析海马不同功能区域小胶质细胞激活的情况。

 

 

 

参考文献

Li Wei, Yupeng Du, Yirui Xie, Xiaopeng Yu, Hui Chen and Yunqing Qiu,Lipocalin-2 Regulates Hippocampal Microglial Activation in Poststroke Depression,Front Aging Neurosci., 13 December 2021 | https://doi.org/10.3389/fnagi.2021.798335.
编译作者:  原代美少女 (Brainnews创作团队) 
校审: Simon (Brainnews编辑部)

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671453, encodeId=1d6016e14538f, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Jan 28 14:43:27 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927951, encodeId=370f192e951ae, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Feb 18 21:43:27 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364772, encodeId=25491364e7238, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389254, encodeId=30f8138925439, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510858, encodeId=c8f1151085854, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082540, encodeId=be6d108254032, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Dec 21 13:03:52 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082538, encodeId=e0fb1082538fa, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Dec 21 12:57:22 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671453, encodeId=1d6016e14538f, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Jan 28 14:43:27 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927951, encodeId=370f192e951ae, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Feb 18 21:43:27 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364772, encodeId=25491364e7238, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389254, encodeId=30f8138925439, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510858, encodeId=c8f1151085854, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082540, encodeId=be6d108254032, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Dec 21 13:03:52 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082538, encodeId=e0fb1082538fa, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Dec 21 12:57:22 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2022-02-18 smlt2008
  3. [GetPortalCommentsPageByObjectIdResponse(id=1671453, encodeId=1d6016e14538f, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Jan 28 14:43:27 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927951, encodeId=370f192e951ae, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Feb 18 21:43:27 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364772, encodeId=25491364e7238, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389254, encodeId=30f8138925439, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510858, encodeId=c8f1151085854, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082540, encodeId=be6d108254032, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Dec 21 13:03:52 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082538, encodeId=e0fb1082538fa, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Dec 21 12:57:22 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2021-12-23 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1671453, encodeId=1d6016e14538f, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Jan 28 14:43:27 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927951, encodeId=370f192e951ae, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Feb 18 21:43:27 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364772, encodeId=25491364e7238, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389254, encodeId=30f8138925439, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510858, encodeId=c8f1151085854, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082540, encodeId=be6d108254032, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Dec 21 13:03:52 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082538, encodeId=e0fb1082538fa, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Dec 21 12:57:22 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1671453, encodeId=1d6016e14538f, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Jan 28 14:43:27 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927951, encodeId=370f192e951ae, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Feb 18 21:43:27 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364772, encodeId=25491364e7238, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389254, encodeId=30f8138925439, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510858, encodeId=c8f1151085854, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082540, encodeId=be6d108254032, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Dec 21 13:03:52 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082538, encodeId=e0fb1082538fa, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Dec 21 12:57:22 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2021-12-23 dzx0922892
  6. [GetPortalCommentsPageByObjectIdResponse(id=1671453, encodeId=1d6016e14538f, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Jan 28 14:43:27 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927951, encodeId=370f192e951ae, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Feb 18 21:43:27 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364772, encodeId=25491364e7238, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389254, encodeId=30f8138925439, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510858, encodeId=c8f1151085854, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082540, encodeId=be6d108254032, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Dec 21 13:03:52 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082538, encodeId=e0fb1082538fa, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Dec 21 12:57:22 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2021-12-21 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1671453, encodeId=1d6016e14538f, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Jan 28 14:43:27 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927951, encodeId=370f192e951ae, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Feb 18 21:43:27 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364772, encodeId=25491364e7238, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389254, encodeId=30f8138925439, content=<a href='/topic/show?id=acf3840e459' target=_blank style='color:#2F92EE;'>#胶质细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84074, encryptionId=acf3840e459, topicName=胶质细胞)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/DC48AC6B5FFD609EED5594C15A97B420/100, createdBy=57dc2500034, createdName=ms1692212821629096, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510858, encodeId=c8f1151085854, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Thu Dec 23 00:43:27 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082540, encodeId=be6d108254032, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Dec 21 13:03:52 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082538, encodeId=e0fb1082538fa, content=好文章,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, createdBy=88b489038, createdName=yangchou, createdTime=Tue Dec 21 12:57:22 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2021-12-21 yangchou

    好文章,谢谢分享。

    0

相关威廉亚洲官网

PLoS One:卒中后抑郁的抑郁症状应评估躯体症状

背景:尽管脑卒中后抑郁症有充分的研究,但关于睡眠障碍、能量损失、食欲减退、注意力不集中等症状是卒中的影响还是抑郁症的一般症状,尚有争议。通过比较抑郁和非抑郁性脑卒中患者和有症状的动脉粥样硬化性疾病的患者的症状,旨在卒中后抑郁和其他患者抑郁症状的相似性和区别。根据这些,判断患者的躯体症状是由于卒中引起还是卒中后发生抑郁引起。方法:进行一项多中心的观察性研究,共有3个医院和7个全科内诊断为颅内出血或缺

Medicine :低血清尿酸与卒中后抑郁相关

卒中后抑郁(PSD)是卒中常见的并发症,并与卒中患者不良预后相关。这篇研究旨在探索PSD患者和血清尿酸的相关性。研究者招募了196了急性缺血性患者和100个健康自愿者。应用尿酸酶PAP法检测入院24 小时血清尿酸水平。卒中后3个月评估患者神经心理学。应用17项汉密尔顿抑郁量表评估抑郁症状。PSD的诊断与DSM-IV抑郁诊断标准一致。应用多变量logistic回归模型进行分析。共有56(28.6%)

PLoS One:卒中后抑郁与TrkB基因多态性相关

背景:脑源性神经营养因子(BDNF)基因多态性作为卒中后抑郁的潜在基因,得到研究,已知其受体和神经营养因子酪氨酸激酶受体B(TrkB)与抑郁症相关。然而,尚未有数据报告PSD和TrkB基因多态性的研究。这篇研究旨在调查TrkB多态性是否与PSD相关。方法:招募312名抑郁症患者(PSD患者)和472个非抑郁症患者为对照组(非PSD患者)。所有患者均采用汉密尔顿抑郁量表(HAMD)评定抑郁严重程度,

PLoS One:食欲紊乱和疲劳可能是卒中后抑郁早期表现

脑卒中后抑郁(PSD)是可能会导致不良预后的一种关键的并发症。然而,在脑卒中急性期PSD,也就是说在卒中后2周或3周,由于共发病而被忽视了。本研究旨在揭示在急性期PSD的突出症状,在发病后1周和1个月后颅内出血(ICH)或脑梗塞(BI)患者的填写抑郁问卷(快速自评抑郁症状:QIDS-SR)。排除意识障碍或失语的患者。49例脑出血患者及222例BI患者在1周,ICH患者在27天,BI患者在1个月时,